文献速递慢性肾脏病血液净化与透析

台湾末期肾病前期按绩效付费项目在晚期慢性肾脏病患者中的经济学评价

Economic evaluation of a pre-ESRD pay-for-performance programme in advanced chronic kidney disease patients.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

该研究基于台湾全民健康保险数据库,采用纵向观察性匹配队列设计,比较参加与未参加末期肾病前期按绩效付费项目的晚期慢性肾脏病患者。结果显示,参加项目者透析发生率与全因死亡风险均更低,且该项目在3年随访期内具有长期成本效果并节省费用。

要点

  • 参加按绩效付费项目与透析发生率降低相关(SHR 0.845,95%CI 0.779-0.916)。
  • 参加按绩效付费项目与全因死亡风险降低相关(SHR 0.792,95%CI 0.673-0.932)。
  • 该项目在晚期慢性肾脏病患者中显示长期成本效果和费用节省。

核心结论

  • 参加按绩效付费项目的晚期慢性肾脏病患者透析发生率和死亡风险均更低。
  • 台湾末期肾病前期按绩效付费项目在晚期慢性肾脏病患者中提供了长期成本效果和费用节省。

研究设计与样本

  • 采用纵向观察性匹配队列研究,使用两个全国性人群基于数据集。
  • 比较匹配的按绩效付费与非按绩效付费晚期慢性肾脏病患者。
  • 使用竞争风险分析、一般线性回归和自举法进行统计分析。

主要发现

  • 参加按绩效付费项目的晚期慢性肾脏病患者透析发生率的亚分布风险比为0.845(95%CI 0.779-0.916)。
  • 参加按绩效付费项目的晚期慢性肾脏病患者全因死亡的亚分布风险比为0.792(95%CI 0.673-0.932)。
  • 开始透析的按绩效付费与非按绩效付费患者生命年分别为2.83和2.74。
  • 开始透析的按绩效付费与非按绩效付费患者调整后增量CKD相关费用分别为114 704新台币(3823美元)和32 420新台币(1080美元)。
  • 未开始透析的按绩效付费与非按绩效付费患者调整后增量其他原因相关费用分别为-3434新台币(114美元)和45 836新台币(1572美元)。

临床怎么用

  • 对于晚期慢性肾脏病患者,参加末期肾病前期按绩效付费项目可能降低透析启动和死亡风险。
  • 该项目在3年随访期内显示出成本效果和费用节省,可支持类似支付政策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The National Health Insurance Administration in Taiwan initiated a nationwide pre-end-stage renal disease (ESRD) pay-for-performance (P4P) programme at the end of 2006 to improve quality of care for chronic kidney disease (CKD) patients. This study aimed to examine this programme's effect on patients' clinical outcomes and its cost-effectiveness among advanced CKD patients. METHODS: We conducted a longitudinal observational matched cohort study using two nationwide population-based datasets. The major outcomes of interests were incidence of dialysis, all-cause mortality, direct medical costs, life years (LYs) and incremental cost-effectiveness ratio comparing matched P4P and non-P4P advanced CKD patients. Competing-risk analysis, general linear regression and bootstrapping statistical methods were used for the analysis. RESULTS: Subdistribution hazard ratio (95% confidence intervals) for advanced CKD patients enrolled in the P4P programme, compared with those who did not enrol, were 0.845 (0.779-0.916) for incidence of dialysis and 0.792 (0.673-0.932) for all-cause mortality. LYs for P4P and non-P4P patients who initiated dialysis were 2.83 and 2.74, respectively. The adjusted incremental CKD-related costs and other-cause-related costs were NT$114 704 (US$3823) and NT$32 420 (US$1080) for P4P and non-P4P patients who initiated dialysis, respectively, and NT$-3434 (US$114) and NT$45 836 (US$1572) for P4P and non-P4P patients who did not initiate dialysis, respectively, during the 3-year follow-up period. CONCLUSIONS: P4P patients had lower risks of both incidence of dialysis initiation and death. In addition, our empirical findings suggest that the P4P pre-ESRD programme in Taiwan provided a long-term cost-effective use of resources and cost savings for advanced CKD patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Hsieh HM, Lin MY, Chiu YW, et al. Economic evaluation of a pre-ESRD pay-for-performance programme in advanced chronic kidney disease patients. Nephrol Dial Transplant. 2017. PMID: 28486670. doi:10.1093/ndt/gfw372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。